EUDA Health Holdings Limited EUDA
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -62.40%
- 1 year
- -70.21%
5D +3.10 (+21.72%)
- Market cap
- 52.01M
- Revenue (ttm)
- 3.81M
- EPS (ttm)
- -1.18
- Shares out
- 37.15M
- Forward P/E
- -68.50
- YTD return
- -62.40%
- 1-year return
- -70.21%
- 50-day average
- 4.51
- Volume
- 180.16K
- Avg volume
- 34.63K
- Open
- 15.30
- Previous close
- 15.02
- Day's range
- 13.99 – 17.75
- 52-week range
- 5.26 – 68.00
- Beta
- -0.00
- Price target
- 6.00 (-65.5%)
Key statistics
- 200-day average
- 3.37
- Enterprise value
- 163.27M
- Price / sales
- 40.06
- Revenue growth
- -13.80%
- Free cash flow
- -686.67K
- Total cash
- 376.21K
- Total debt
- 2.76M
- Short % of float
- 0.04%
Fundamental scorecard
7 of 25 checks passed on EUDA’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
About EUDA Health Holdings Limited
EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates in two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, and residential apartments, as well as condominiums. EUDA Health Holdings Limited is headquartered in Singapore.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- Singapore
- Website
- euda.com
News
EUDA Health Subsidiary Melana International Wins Golden Bull Award 2026 Singapore
12 Health Care Stocks Moving In Friday's Intraday Session
EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore
EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products
EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies
Phreesia (NYSE:PHR) & EUDA Health (NASDAQ:EUDA) Head-To-Head Review
EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency
EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development
EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities
Your note
Sign in to keep a note on EUDA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Hudson Bay Capital Management Lp | 3.25% | 800,000 | 3.29M | Sep 29, 2024 |
| Citadel Advisors Llc | 0.14% | 33,824 | 139.02K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.07% | 16,038 | 65.92K | Sep 29, 2024 |
| Walleye Capital LLC | 0.07% | 16,569 | 68.10K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 3,663 | 15.05K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 16,038 | 65.92K | Oct 30, 2024 |
